0001628280-26-070989
SEC filingOmada Q3营收$91M增34%、扭亏为盈净利$7M,糖尿病与高血压项目驱动会员达110万并上调全年指引。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Revenue | $91.3M | $68.0M | 34% |
| Gross Margin (GAAP) | 76% | 66% | — |
| Gross Margin (Non-GAAP) | 78% | 68% | — |
| Operating Income | $4.8M | $(2.5)M | — |
| Net Income | $6.6M | $(3.2)M | — |
| Diluted EPS (GAAP) | $0.10 | $(0.06) | — |
| Adjusted EBITDA | $12.4M | $2.4M | — |
| Total Members | 1.1 million | — | 36% |
| 期间 | 指标 | 指引 | 口径 |
|---|---|---|---|
| FY2026 | Revenue | $344M–$346M | N/A |
| FY2026 | Adjusted EBITDA | $32M–$34M | Non-GAAP |
本季增长由糖尿病与高血压项目驱动,服务收入$85.1M、硬件收入$6.2M,Total Members达1.1 million(同比+36%),平均会员留存升至约2年4个月(同比+10%),带动trailing 12-month revenue per Total Member同比增约5%至$294。GAAP毛利率由66%升至76%,Non-GAAP毛利率由68%升至78%,叠加经营杠杆,GAAP经营利润转正至$4.8M、净利润$6.6M,Adjusted EBITDA达$12.4M(margin 14%,去年4%)。
全年2026指引上调:营收$344M–$346M(前值$334M–$340M,中值约33%增长),Adjusted EBITDA $32M–$34M(前值$21M–$27M,中值约同比改善$27M、约5.5倍);公司未提供GAAP净利润指引及调节表。资产负债表端现金及等价物$243.2M,前九个月经营现金流$7.3M、自由现金流$2.5M均转正。需关注客户与渠道伙伴集中度、会员参与度及医疗监管合规等风险(详见Exhibit 99.1前瞻性声明)。